Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee. These RSUs vest over one year starting from this new employee's date of hire.

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health (NASDAQ: JAGX ) stock is falling on Monday as the company prepares for a reverse stock split later this week. Jaguar Health is going to enact a one-for-60 reverse stock split on Thursday.

Why Is Jaguar Health (JAGX) Stock Down 40% Today?

Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-60, on Thursday, May 23, 2024 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President and CEO Carol Lizak - CFO Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements, relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and productive initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Jaguar Health, Inc. (JAGX) Q1 2024 Earnings Call Transcript

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product REMINDER: Jaguar to host investor webcast Tuesday, May 14th at 8:30 a.m. Eastern regarding Q1 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2024 financial results and provided Company updates.

Jaguar Health Reports First Quarter 2024 Financial Results

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar's novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults. Napo Therapeutics has also submitted a CTA to AIFA, the Italian health authority, for the conduct of a clinical trial in pediatric patients with microvillus inclusion disease (MVID), and the approval request process is also underway for this trial in the United Arab Emirates with Dubai Health.

Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 14, 2024, at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.

Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

Ginkgo Bioworks Holdings

FuelCell Energy

There's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?

Want $10,000? Invest $1,000 in These 3 Penny Stocks Now

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with the Center for Veterinary Medicine (CVM) of the U.S. Food and Drug Administration (FDA) for the company's novel plant-based prescription drug crofelemer to treat general, non-infectious diarrhea in dogs. Crofelemer delayed-release tablets, under the name Canalevia®-CA1, received conditional approval in December 2021 from the FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

Crofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs

Next.e.GO NV

Faraday Future Intelligent Electric

Investing in tech penny stocks presents an exciting opportunity for investors looking to expand their portfolios with potentially high-reward options. Penny stocks are typically shares of small companies traded at low prices, often under $5.

Investing in Tech Penny Stocks Right Now, 3 Tips

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE). Additionally, at the conference Napo is sponsoring a panel discussion titled "Masterclass in Congenital Diarrhea" which will focus on microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder.

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)

Agba Acquisition Ltd

NewGenIvf Group Ltd

Penny stocks represent a unique opportunity for investors aiming to expand their portfolios without a significant initial investment. Trading penny stocks can yield high returns due to their low purchase price, making them an appealing option for both seasoned traders and newcomers to the stock market.

3 Obstacles Investors Face When Buying Penny Stocks

Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient advocacy program at ONS Congress SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the Oncology Nursing Society (ONS) Congress taking place April 24-28, 2024 in Washington, DC. "We look forward to driving awareness among the oncology nursing community at this event about Jaguar's expanding focus on cancer supportive care," said Lisa Conte, Jaguar's president and CEO.

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy. "Cathy Collis was instrumental in bringing about the Gelclair in-license agreement.

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Jaguar Health (NASDAQ: JAGX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment. Jaguar Health is looking to treat chemo mouth, a side effect of chemotherapy, with Gelclair.

Why Is Jaguar Health (JAGX) Stock Up 44% Today?

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market, for Venture Life's FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market. "We are very happy to have executed the in-license agreement for Gelclair - and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO.

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care

Former meme stock Jaguar Health (NASDAQ: JAGX ) has won the approval of certain measures meant to help maintain its Nasdaq listing. These include an extension to Aug. 13 to regain compliance by getting its price over $1 as well as JAGX stockholder approval of a potential reverse stock split.

What Is Going on With Jaguar Health (JAGX) Stock Today?

Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024 (the "Special Meeting"). Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting.

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders

Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before August 13, 2024.

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr. Radaelli is a member of the board of directors of Napo Therapeutics, the Jaguar family company established in Italy in 2021 that focuses on expanding crofelemer access in Europe, and temporarily served as Napo Therapeutics' Interim Executive Director.

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript

Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million Top line results expected forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea REMINDER: Jaguar to host investor webcast Monday, April 1st at 8:30 a.m. Eastern regarding Q4 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2023.

Jaguar Health Reports 2023 Financial Results

Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.

Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates

Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed a binding term sheet covering the exclusive license and commercialization agreement ("the Agreement") for Jaguar's novel plant-based, FDA-approved prescription drug crofelemer with Turkish specialty pharmaceutical company Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret, A.S. ("GEN") (GENIL.IS).

GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market

News for Jaguar Health Stock (JAGX)